Galapagos NV (Galapagos NV) Debt-to-Equity

: 0.00 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

Galapagos NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.1 Mil. Galapagos NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.4 Mil. Galapagos NV's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3,048.6 Mil. Galapagos NV's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Galapagos NV's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of Galapagos NV was 0.01. The lowest was 0.00. And the median was 0.01.

GLPGF's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.145
* Ranked among companies with meaningful Debt-to-Equity only.

Galapagos NV Debt-to-Equity Historical Data

The historical data trend for Galapagos NV's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.01

Galapagos NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.01	0.01	0.01	0.01	-

Competitive Comparison

For the Biotechnology subindustry, Galapagos NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galapagos NV Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Galapagos NV's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Debt-to-Equity falls into.

Galapagos NV Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Galapagos NV's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.073	+	5.391)	/	3048.6
	=	0.00

Galapagos NV's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.073	+	5.391)	/	3048.6
	=	0.00

Galapagos NV (OTCPK:GLPGF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Galapagos NV Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV (Galapagos NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (OTCPK:GLPGF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GLPG:USA GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.